81 Biggest Movers From Yesterday
Gainers
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results.
Oppenheimer Initiates Coverage On AN2 Therapeutics with Outperform Rating, Announces Price Target of $22
Oppenheimer analyst Kevin DeGeeter initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Outperform rating and announces Price Target of $22.
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15
AN2 Therapeutics Inc (NASDAQ:ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering,…
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Preview: An2 Therapeutics, Inc Set To IPO Tomorrow
AN2 Therapeutics, Inc (NASDAQ:ANTX) IPO will take place March, 25 on the NASDAQ exchange under the ticker ANTX.
The company is offering shares at an expected price between $14.00 and $16.00 per share with an insider lock-up period of 180 days ending on September 21, 2022.